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Factors affecting the progression of renal disease in autosomal-domi.
nant polycystic kidney disease. Autosomal-dominant polycystic kidney
disease results in renal failure at a varying age from childhood to old
age. We postulated that factors other than the culprit gene alone
contribute to the course of progression of the renal failure. We studied
580 subjects with autosomal-dominant polycystic kidney disease and
194 unaffected family members. We calculated survival curves to
end-stage renal failure or death and developed a linear model for testing
the effects of single or multiple variables on the progression of renal
failure as estimated from the reciprocal of serum creatinine. Fifty-two
subjects died and 94 reached end-stage renal failure during the period of
observation, yielding functional survivals of 71% at age 50 years, 53%
at 58 years and 23% at 70 years. The following variables were
independently associated with worse mean renal function at a given age
(P value less than 0.01): the PKDI gene, younger age at diagnosis, male
gender, hypertension, increased left ventricular mass, hepatic cysts in
women, three or more pregnancies, gross hematuria, urinary tract
infections in men and renal size expressed as renal volume. The
following were not associated significantly with the course of renal
function: gender of affected parent, mitral valve prolapse, intracranial
aneurysms, any pregnancy, hepatic cysts in men and urinary tract
infections in women. The identification of unalterable maleficent factors
such as the PKDI gene and male gender permit more informed
counseling while the identification of alterable factors such as hyper-
tension, number of pregnancies and recurrent urinary tract infections
provides the clinician with the opportunity to modify these factors and
improve the management of patients with autosomal-dominant polycys-
tic kidney disease.
Autosomal-dominant polycystic kidney disease (ADPKD),
the most common hereditary disease in the United States,
accounts for 10 to 12% of all end-stage renal disease in this
country. Yet many ADPKD patients never reach end-stage
renal failure and many reach end stage only late in life.
Churchill et a! [1] and Parfrey et al [2], respectively, have
reported that 57% and 50% of ADPKD patients are alive
without end-stage renal disease at age 58 years. All individuals
with ADPKD bear a gene that is expressed in clinically diag-
nosed disease as multiple renal cysts. Despite this common
property of disease expression, patients with ADPKD exhibit
marked non-uniformity in the progression to end-stage renal
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failure. This suggests that factors in addition to the culprit gene
contribute importantly to the progression of renal failure.
Identification of these factors might allow specific intervention
to remove or modify their impact and thus favorably modulate
the course of renal disease in ADPKD. In order to identify such
maleficent factors, we analyzed an array of variables in a very
large population of individuals with ADPKD.
Methods
The study population consisted of 580 subjects with ADPKD
confirmed by imaging studies, surgical specimens or autopsies
and 194 unaffected members of the families of these subjects.
Each of these subjects was seen at least once at the University
of Colorado during the past 25 years. Limited clinical data from
279 ADPKD subjects were gathered largely prior to 1985
whereas the data from 301 ADPKD subjects and their 194
unaffected relatives were obtained during formal investigation
in the General Clinical Research Center at University Hospital
during 1985 through 1990. The former group was utilized only in
the survival analysis.
We previously have reported our methods and definitions and
therefore present only brief descriptions here [3, 4]. ADPKD is
defined as the presence of five or more renal cysts distributed
between both kidneys. Family members were classified as
unaffected if they had no cysts. Both static and real-time
ultrasound images were used to determine kidney and cyst
characteristics [4]. Gene linkage analysis was attempted in 174
families studied since 1985 using a panel of markers for the
locus of the putative PKD1 gene on the short arm of chromo-
some 16 [5, 6]. Absence of linkage to chromosome 16 markers
defined a family as PKD2 [7]. Families that were unable to be
classified due to lack of informative members or sufficient
numbers of subjects were included with PKD1 families for
analysis due to the greater than 90% likelihood of that genetic
type [61. Hypertension was defined by one of the following:
current antihypertensive pharmacological treatment, sitting
systolic pressure over 150 mm Hg, or sitting diastolic pressure
greater than 90 mm Hg at the time of study visit. Hepatic cystic
disease required only one detectable cyst within the liver. One
hundred thirty-four subjects underwent echocardiography; they
were classified as positive or negative for mitral valve prolapse
based on standard criteria and their left ventricular masses were
determined by standard methodology and calculations which
1311
1312 Gabow et al: Factors affecting renal disease in ADPKD
adjust for body surface area [8, 9]. Subjects were included in the
analysis for intracranial aneurysm if they had been examined
formally by cerebral arteriography or computed tomography or
had suffered a documented ruptured intracranial aneurysm.
Subjects were considered to have gross hematuria if they
gave a history of observing blood in the urine and microhema-
tuna if the urinalysis at University Hospital showed 1 to 5
rbc/hpf or greater. Subjects were classified as positive for
urinary tract infections if they had been told they had two or
more infections (often culture data were not available), Only
subjects who had a known or suspected affected parent were
included in the analysis for the effect of parental gender. Age of
diagnosis was considered to be the age at which a subject was
first informed that he or she had ADPKD. The age at terminal
event was that at the time of onset of dialysis or transplantation
or at death in the non-dialyzed, non-transplanted subjects. In all
other subjects, the age at last determination of serum creatinine
was the time of censoring.
Statistical methods
The Kaplan-Meier method [10] was used to calculate survival
curves until a terminal event as described above. This is not a
true population-based sample, as the study subjects were not
chosen randomly from a well-defined population and not all
members of each family were included in the study. Moreover,
probands were not excluded. However, the survival analysis is
included because of the large size of the study group. The
log-rank test was used to compare survival curves between
groups.
The reciprocal of serum creatinine was used to analyze the
progression of renal function with age because this variable had
been measured in all subjects for periods of as long as 25 years.
The method of Jones and Boadi-Boateng for unequally spaced
longitudinal data with serial correlation and random subject
effects was used [11]. The Jones and Boadi-Boateng paper
describes in detail the methods utilized to analyze these data.
An example of how the mean curves are obtained from individ-
ual data is shown in Figure 1. Initially an equation for the mean
curve for all subjects is specified. The mean curve is derived
from the curves of the individual subjects which vary about the
mean curve (random subject effects). The analysis identifies and
incorporates serial correlation which adjusts for the fact that
measurements taken closer together in time from a given
subject have higher correlations than measurements taken
further apart in time, Subjects with a single data point provide
no information concerning the slope, but do provide informa-
tion on the random subject effect and are therefore included in
the analysis. Exact maximum likelihood estimates of the un-
known parameters are computed. Models are compared using
likelihood ratio tests when appropriate, If a model with a
greater number of parameters is not significantly different from
a simpler model, then the simpler model is preferred.
Three equations were evaluated for expressing the relation-
ship of reciprocal serum creatinine and age: a linear equation, a
quadratic polynomial with group intercepts and slopes con-
strained to be equal at age 0 years, and a cubic polynomial with
group intercepts and slopes constrained to be equal at age 0 and
no quadratic terms.' The linear model, the simplest and histor-
ically applied method [121, implies that the rate of change of
renal function is constant over time. The quadratic and cubic
models allow the rate of change to increase over time. We
restored the linear term to the cubic model used by Franz and
Reubi [13] because we found it to be significant. In the quadratic
and cubic equations the intercepts for each group were con-
strained to be equal at age 0 because there was no reason to
believe that differences in renal function between groups would
be present at birth. However, we used only serum creatinine
values obtained after the eighteenth birthday, therefore it is
possible that differences between groups exist between ages 0
and 18 years. If that is the case, the quadratic and cubic models
would result in curves that separate before age 18. Since this
separation is not possible with the linear model, we allowed the
intercepts to be unconstrained at age 0 for that model.
We then tested the influence of the following factors on the
above models of progression of renal failure: gender, hyperten-
sion, mean renal volume, hematuria, and possible interactions
among the variables. The three models were fit using data from
the PKD1 and unclassified ADPKD families and were com-
pared using Akaike's Information Criterion [14]. Serial corre-
lation was tested and was found to be present in the data. The
linear model with separate intercept and slope coefficients for
each line provided the best fit to these data.
We then tested a large array of factors for their influence on
the progression of renal disease including both dichotomous
(gene type, affected parent, gender, hypertension, mitral valve
prolapse, aneurysm, hepatic cysts, pregnancy, hematuria, and
Equations of models. Linear: 1lS. = b0 + b, x age + b2 x variable
+ b3 x age x variable. Quadratic with intercept and slope constrained
to be equal at age 0: 1ISr = b0 + b, x age + b2 x age2 + b3 x age2 ><
variable. Cubic with group intercepts constrained at age 0, single linear
term, no quadratic terms: 1IS. = b0 + b, x age + b2 x age3 + b3 x age3
)< variable.
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Fig. 1. Schematic representation of the methodology used to create
group mean curves. The asterisks represent hypothetical serum creat-
mine values for three individuals with 2, 3, and 4 observations at
different ages. An individual curve (in this case, a line) is computed for
each subject. Examples of possible individual curves are shown, These
curves are then combined to create mean curves for groups separated
by variables such as gender or the presence or absence of hypertension.
Also shown is a subject with a single data point (dot). This value does
not contribute information on the slope of the group mean curve, but
does provide information on the vertical placement of the line and on
the random subject effect.
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Fig. 2. Cumulative survival to end-stage renal disease or death for 580
individuals with autosomal-dominant polycystic kidney disease. There
were 146 events, with 94 individuals reaching end-stage renal disease
and 52 deaths.
urinary tract infections) and continuous variables (age of diag-
nosis, left ventricular mass, mean renal volume, and body
surface area). Each variable was tested separately using the
linear model. If the intercept term for the line with the variable
did not differ from that for the line without the variable, the
intercepts were constrained to be equal at age 0 (see Fig. 9).
Similarly, if the slope coefficient for the line with the variable
was not significantly different from the slope coefficient for the
line without the variable, the model was then run with the
slopes constrained to be equal (Figs. 6, 8, and 12). In that
instance there are two possible interpretations — either the two
groups differ in mean serum level by a constant amount over
their lifetimes, or the two groups actually began at the same
mean serum creatinine level in childhood and diverged from
each other before age 18 or in young adulthood so that the best
fit lines over the age range studied were parallel. If the slopes of
the lines in the models are equal, a significant difference
between the two lines indicates that the two groups are statis-
tically different with respect to serum creatinine concentration
over time. The P value takes into account both the magnitude
and the variability of this difference.
For dichotomous variables (such as those depicted in Figs. 5,
6, 8, 9 and 12), the model without the variable was a single line
representing the mean for the entire group, and the model
containing the variable consisted of two lines for the subject
groups defined by the presence or absence of the variable. The
graphs depict the group mean lines with standard error bars at
ages 20, 40, and 60. For continuous variables (such as those
depicted in Figs. 7 and 11), the model without the variable was
a single line, and the model with the variable consisted of a
family of lines dependent on the individual values for the
continuous variable. For continuous variables the graphs depict
the mean lines for selected values of the continuous variable,
namely the 10th, 50th, and 90th percentiles (Figs. 7 and 11).
Variables were considered to have a significant effect on renal
function if a model containing the variable had a significantly
greater maximum likelihood than a model not containing the
variable, that is, the model including the variable produced a
significantly better fit to the data than the model without the
variable as determined by the likelihood ratio test. The P value
Age, years
Fig. 3. Cumulative survival to end-stage renal disease or death for30
individuals from one family with autosomal dominant polycystic kidney
disease unlinked to tnarkers on chromosome 16 (PKD2) and 550
individuals whose autosomal-dominant polycystic kidney disease is
assumed to be linked (PKDI). There were 9 events in the PKD2 group
and 137 events in the PKDI group. The PKD1 group had significantly
worse survival, P < 0.01,
refers to this difference. For continuous variables it does not
necessarily reflect differences between the lines of the specific
percentiles graphed (Figs. 7 and 11). Because of the number of
variables tested, tests of significance were carried out at the
0.01 significance level. To test for possible confounding effects
interacting among variables such as gender and hypertension
(Fig. 10), models were run with more than one variable at a time
to test which variables contribute to the effect on renal function
in the presence of the others.
We have utilized the reciprocal of serum creatinine to assess
renal function since it has been widely used previously and that
measurement is available over a long period of time in this
population. Clearly the method is not perfect for an array of
reasons centering around the reliability of the serum creatinine
measurement itself as a measure of renal function which relates
to the effect of muscle mass, variable creatinine production and
extrarenal removal of creatinine [15]. However, the methodol-
ogy utilized in this study does provide important advantages
over previous methods which utilized the reciprocal of serum
creatinine in that these factors have less of an effect when a
mean line is derived from many points from many patients
rather than a single patient line. In this method the effect of
"noise" in an individual is attenuated.
Results
Survival analysis
One hundred forty-six of the entire 580 ADPKD subjects had
a terminal event, either death (N = 52) or development of
end-stage renal disease (N = 94). These events were distributed
such that 71% of subjects were alive without end-stage renal
disease at age 50; 53% at age 58 and 23% at 70 years of age (Fig.
2). Among the ADPKD subjects, those classified as PKD1 (N =
550) had worse survival than the PKD2 subjects (N = 30; P <
0.01, Fig. 3). Among the PKD1 subjects, men (N = 249) had a
lower survival rate than women (N = 301; P < 0.01, Fig. 4).
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Fig. S. The effect of autosomal-dominant kidney disease status on
renal function, The ADPKD group consisted of 301 adult subjects and
the NADPKD group consisted of 194 adult relatives of the ADPKD
subjects. The lines depicted are the estimated mean curves for each
group based on a linear model for unequally spaced longitudinal data
with serial correlation and random subject effects. The estimated mean
lines are significantly different, P C 0.001.
Factors affecting progression
The 301 subjects with ADPKD who participated in our formal
General Clinical Research Center study had a total of 1585
serum creatinine observations during periods spanning up to 25
years. Sixty percent of subjects had three or more creatinine
determinations (overall range 1 to 46 observations); in 36% of
subjects the observations spanned five or more years (overall
range 0 to 25 years). One hundred ninety-four subjects free of
renal cysts had a total of 377 serum creatinine observations.
Renal function estimated as the reciprocal of serum creatinine
differed significantly with time between the ADPKD subjects
and their unaffected family members. As expected, subjects
with ADPKD had a significantly greater deterioration than did
unaffected family members who showed very little decrease in
renal function during a normal life span (Fig. 5). It is likely that
the unaffected family members did have some decrease in renal
function with advancing age, but the decrease in creatinine
clearance is matched in part by the decrease in serum creatinine
concentration with age which results from the decrease in
muscle mass. Therefore the serum creatinine tends to remain
stable over the years due to these opposing effects. Hence, a
method which utilizes serum creatinine will show little decrease
in renal function with age in subjects without kidney disease.
To examine the effect of gene type on renal function in
ADPKD, we compared the course of the 281 PKD1 (114
subjects in 39 families) and unclassified subjects (167 from 134
families) with 20 subjects from one family who were classified
as PKD2. PKD2 subjects had a significantly less aggressive
course of renal disease (P < 0.001, Fig. 6). ADPKD subjects
with the PKD I gene would exceed a serum creatinine concen-
tration of 1.5 mgldl (130 pmol/liter) by 49 years of age while the
PKD2 subjects on average would not be expected to have their
serum creatinine exceed the normal range until after age 7t1.
Since all the PKD2 individuals in this analysis were from one
family, it is possible that this represents a family difference
independent of gene type. In this regard, however, all four of
the large families in this study with definite PKD 1 had a similar
pattern of decline of renal function and each was significantly
different from the PKD2 family. The substantial difference
between the ADPKD subjects with the PKD1 and PKD2 genes
led us to exclude the PKD2 subjects from all subsequent
analyses. The remaining 281 subjects had a total of 1387 serum
creatinine determinations.
Table 1 contains the frequencies of the dichotomous variables
of interest in these subjects. We had noted previously that a
greater percentage of subjects in our population with diagnosis
in childhood had an affected father [16]. Therefore, we com-
pared the course of the renal disease in subjects with an affected
father (N = 133) and those with an affected mother (N = 113).
Those subjects in whom the affected parent was not known
were excluded (N = 35). There was no significant difference in
the progression of renal disease between the two groups.
Previous data from our population had suggested that chil-
dren diagnosed prior to the first year of life had a worse
prognosis than children diagnosed at an older age [16]. There-
fore, we examined the effect of age of diagnosis on outcome.
Those individuals diagnosed earlier in life had worse renal
function at any given age (P C 0.001). The data are displayed at
the 10th, 50th and 90th percentiles of our study group (Fig. 7).
We next examined the effect of gender. Females with
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0 20 40 60 80 Fig. 6. The effect of gene type on renalfunctian. The 20 PKD2 subjects
are in a family whose ADPKD gene is definitely not located on the short
arm of chromosome 16. The PKD1 subjects are in families where the
Fig. 4. Cumulative survival to end-stage renal disease or death for 249 ADPKD gene is linked to markers on chromosome 16 (N = 114) or is
men and 301 women with autosomal-dominant polycystic kidney dis- assumed to be linked (N = 167). The estimated mean lines are
ease assumed to be linked to markers on chromosome 16 (the PKDI significantly different, P C 0.001.
group of Fig. 3). The men had 72 events, the women 65. Men had
significantly worse survival, P C 0.01.
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PKDI subjects
With
condition
Variable N N %
Gender of affected parent (= father) 246 133 54
Gender (= male) 281 111 40
Hypertension 281 197 70
Mitral valve prolapse 134 41 31
Intracranial aneurysms 52 11 21a
Hepatic cysts 281 138 49
Any pregnancy (women only) 170 135 79
Three or more pregnancies (women only) 170 75 44
Gross hematuria 281 122 43
Urinary tract infections 281 123 44
a Subjects with known ruptured intracranial aneurysms or intracra-
nial aneurysms seen with arteriography, most of whom were hyperten-
sive, were compared with hypertensive subjects who demonstrated no
evidence of intracranial aneurysm with computed tomography or arte-
riography. Therefore, this does not reflect the frequency of aneurysms
in the overall population.
Fig. 7. The effect of age of diagnosis on renal function. The 10th
(dotted line), 50th (dashed line), and 90th (solid line) percentiles for age
of diagnosis in our population are displayed. Age of diagnosis had a
significant effect on renal function, P < 0.001. The P value refers to the
aggregate relationship.
Fig. 8. The effect of gender on rena/function. The groups consisted of
111 males and 170 females. The effect of gender is significant, P <
0.001.
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Fig. 9. The effect of blood pressure on rena/function. The normoten-
sive group (N = 84) had no history of hypertension and were normoten-
sive at study visit. The hypertensive group (N = 197) either were
receiving medication for hypertension or had sitting systolic andlor
diastolic hypertension as defined in the text. The effect of hypertension
is significant, P < 0.001.
Age, years
Fig. 10. The combined effects of gender and blood pressure on renal
function. The solid line is the mean line for normotensive females;
dashed line normotensive males, dotted line hypertensive females,
starred line hypertensive males. The P value for gender in the presence
of hypertension in the model is less than 0.001, as is the P value for
hypertension in the presence of gender in the model.
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because adjustment for height or body surface area did not
0 67 remove the gender effect.We hypothesized that hypertension adversely affects the
course of the renal disease. In fact, hypertensive subjects had
1.0 worse renal disease progression than normotensive subjects (P
<0.001, Fig. 9). This effect of hypertension was marked in that
serum creatinine exceeded 1.5 mgldl (130 mol/liter) at 47 years
2.0 of age in hypertensive subjects, 19 years before the normoten-
sive patients. Because males are more frequently hypertensive
________________________________
than females, the effects of hypertension and gender were
15 20 25 30 35 40 45 50 55 60 65 70 75 analyzed together. The effect to worsen the progression of renal
disease is maintained when gender is included with hyperten-
sion in the model (P < 0.001, Fig. 10).
Because our definition of hypertension in part classified
subjects on the basis of an office blood pressure, we examined
the effect of a more specific marker of biologically significant
hypertension on renal function, left ventricular mass (N = 129).
Increasing left ventricular mass was associated with a worse
renal outcome (P < 0.001, Fig. 11). Those subjects whose left
ventricular mass was in the 10th percentile for the group
reached a serum creatinine concentration of 1.5 mg/dl (130
tmo1Jliter) at 56 years of age compared to 44 years of age for
those with a left ventricular mass in the 90th percentile.
ADPKD had a significantly better course of renal disease than
did ADPKD males (P < 0,001, Fig. 8). This relationship of
gender to the course of renal disease was not simply a reflection
of differing muscle mass on serum creatinine concentration
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Fig. 12. The effect of hematuria on renal function. The subjects
included in the hematuria group had one or more episodes of gross
hematuria. The effect is significant, P < 0.01.
Not all ADPKD subjects have extrarenal manifestations. We
hypothesized that extrarenal involvement marked more severe
systemic disease and might reflect more aggressive renal dis-
ease as well. Therefore, we compared the courses of renal
disease in subjects with and without extrarenal involvement.
No significant differences in the course of renal disease were
seen between those with and without mitral valve prolapse or
intracranial aneurysms. However, subjects with hepatic cysts
have more severe renal disease than subjects without hepatic
cysts (P < 0.01). Since the severity of hepatic cystic disease
relates to gender, we examined the groups by gender. In women
but not in men the presence of hepatic cysts was associated
with worse renal function after age 37 years (P < 0.001).
The interaction of the influences of female gender and hepatic
cysts on renal function and the previously described influence
of pregnancy on hepatic cysts [17] led us to examine the effect
of pregnancy on renal function. Women who had never been
pregnant did not differ from those who had experienced a
pregnancy. However, women with three or more pregnancies
had worse renal function after age 41 years than women who
had fewer than three pregnancies. Women having three or more
pregnancies reached a serum creatinine of 1.5 mg/dI (130
,tmol/liter) by age 51, whereas those with fewer pregnancies
reached this level by age 59 (P < 0.01). Pregnancies were
grouped in this way rather than examined as a continuous
Variable P value Comments
ADPKD status <0.001 Unaffected family members
show little renal function
deterioration
Gene type <0.001 PKDI subjects have worse
renal function than PKD2
subjects
Gender of affected NSA
parent
Age at diagnosis <0.001 Subjects diagnosed at an earlier
age have worse renal
function
Gender <0.001 Men have worse renal function
than women
Hypertension <0.001
Left ventricular mass <0.001
Mitral valve prolapse NS
Intracranial aneurysms NS
Hepatic cysts <0.01 NS for men; P < 0.001 for
women
Any pregnancy NS Women only
Three or more <0.01 Women only
pregnancies
Gross hematuria <0.01
Urinary tract infections <O.Olb Borderline for men (P = 0.013);
NS for women
Mean renal volume <0.001
variable because the data were greatly skewed, making the
analysis sensitive to the effect of outliers.
Episodes of gross hematuria were associated with worse
renal outcome. Subjects with one or more episodes of gross
hematuria had worse renal function at any given age than
subjects without this complication (P < 0.01, Fig. 12). Simi-
larly, subjects with microscopic hematuria had a significantly
worse outcome than subjects without microscopic hematuria (P
<0.01).
We also examined the relationship of urinary tract infections
to the progression of renal disease. Since this symptom was
more common in women than men, we examined the groups
separately. In women urinary tract infections did not appear to
affect renal outcome. However, men with urinary tract infec-
tions appeared to have worse renal function than men without
this complication (P 0.013).
Some have speculated that the ultimate cause of renal failure
in ADPKD is the compression of normal renal parenchyma by
cysts. Therefore, we examined the relation of renal structure to
renal functional deterioration. The larger the renal volume the
more aggressive was the course of the renal disease (P < 0.001).
The results of the assessment of the effects of individual
variables on renal function are summarized in Table 2. A
number of the factors which are associated with a more
aggressive course of renal disease tend to relate to each other;
therefore, we examined these variables together in each gender
(Table 3). In women, age of diagnosis, hypertension, three or
more pregnancies, hepatic cysts, hematuria, and renal volume
0
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Table 2. Summary of variables tested individually for their effects on
renal function in ADPKD
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Fig. 11. The effect of left ventricular mass on renal function, The P
value refers to the overall relationship. The 10th (solid line), 50th
(dashed line), and 90th (dotted line) percentiles of left ventricular mass
for our population are displayed. The overall P value for the effect of
left ventricular mass on renal function is less than 0.001.
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a NS, not significantb As a group, subjects with urinary tract infections had better renal
function at a given age than other subjects because the subjects with
urinary tract infections were predominantly women and the gender
effect dominated.
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Table 3. Results of multiple variable analysis separated by gender
Males Females
Significant variables Age at diagnosis
Hypertension
Gross hematuria
Urinary tract infections
Mean renal volume
Age at diagnosis
Hypertension
3 or more pregnancies
Hepatic cysts
Gross hematuria
Mean renal volume
Non-significant Gender of affected Gender of affected
variables parent
Hepatic cysts
parent
Urinary tract
infections
were significantly and independently related to worse renal
function. In males age of diagnosis, hypertension, hematuria,
urinary tract infection and renal volume were significantly and
independently related to renal functional impairment.
Discussion
End-stage renal failure from autosomal-dominant polycystic
kidney disease is the most common serious sequela of the
disease. Early descriptions conveyed this as an almost inevita-
ble outcome striking in middle age. Dalgaard reported the mean
age for death was 50 years of age [18]. Although the survival
analysis presented here is not derived from a true population-
based sample, it agrees remarkably well with two other recently
reported studies, reflecting similarly improved outcomes with
about a 50% occurrence of end-stage renal failure and/or death
by age 58, compared to ages 73 and 59 in the other recent
studies [1, 2]. This improvement may be more artificial than real
because patients with milder disease may have been excluded
from early studies due to inability to identify ADPKD early in
the course of the disease. For example, in Dalgaard's study 9%
of the patients were diagnosed by palpation and 38% by autopsy
[181. Nonetheless, it is important that clinicians understand the
more benign nature of the disease as diagnosed in the current
era in order to counsel their patients appropriately.
Although the overall outlook for the disorder is better than
previously thought, there is considerable variability in the age
of end-stage renal disease which may occur from the first year
of life [16, 19] to over age 80 [201. This makes prognosis for the
individual patient difficult and emphasizes the need for addi-
tional predictive factors. Moreover, the variability in age of
development of end-stage renal disease clearly indicates that
factors other than the presence of the gene alone must modulate
the progression of the renal disease. Thus, we have attempted
to clarify these factors to aid the clinician in prognosis as well as
to provide means hopefully to ameliorate the course of the
disease.
Our observation that PKD2 is a milder form of renal disease
confirms the findings of Parfrey et al [2]. This corroboration is
important since it is not clear whether all ADPKD families not
linked to chromosome 16 represent one genetic mutation. That
is, there could be genes PKD2, PKD3, etc. Thus, the similarity
in Parfrey's 18 subjects from two PKD2 families and our 20
subjects from one PKD2 family is consistent with homogeneity
of PKD2. The parallel nature of the mean lines of progression of
renal function for PKD1 and PKD2 suggests that the factor(s)
which separates the two groups occurs early in life, as might be
expected from an inherent genetic difference. The considerably
later mean age of end-stage renal disease between PKD1 and
PKD2 should influence the physician's counseling of patients
when gene type is known. Ultimately the putative genes for
both ADPKD types will be identified. When this occurs indi-
viduals, not entire families, can be tested to define the gene type
and carrier status and testing for prognostic information may
then represent a valid reason for determining the gene type in a
given ADPKD patient.
It is reasonable to suspect that those subjects with an earlier
age of onset would have a more severe disease and hence earlier
age of onset of renal impairment than subjects who manifested
the disorder later in life. In fact, we have previously shown that
at one extreme, children with onset in utero or in the first year
of life appeared to do worse [16]. Our current data suggest this
effect is broader than the effect for those with neonatal onset.
However, a caveat is that age of diagnosis is most often age of
testing rather than manifestation of disease. Definitive data on
this effect will require serial studies of gene positive subjects
from birth.
The gender effect on ADPKD has been noted in both human
ADPKD and animal models. Dalgaard noted that at age 50 more
ADPKD men were dead than ADPKD women [18J. More
recently, Gretz et al reported that women enter end-stage renal
disease on average six years later than men [211. In this regard
it is of interest that a heterozygote rat model of renal cystic
disease which has a clinical course that approximates ADPKD
yields more severely affected males than females [22]. We had
originally hypothesized that the greater frequency of hyperten-
sion in males (82 vs. 62%, P < 0.001) might account for this
gender effect. However, as we have shown, both gender and
blood pressure have independent effects on progression. The
reason for the gender difference is not apparent in our data. Our
paucity of data prior to age 18 prevents us from establishing if
puberty is the point of division of the mean curves.
The highly significant effect of increasing blood pressure and
sustained hypertension on the progression of renal disease is
striking. As early as 1934, Oppenheimer reported data suggest-
ing a negative association of hypertension with renal function
[23]. Of the 21 normotensive ADPKD subjects in his study 10
(48%) had impaired renal function, while 23 of the 26 hyperten-
sive ADPKD subjects (88%) had impaired renal function. More
recently Iglesias et a! demonstrated significantly worse kidney
survival in ADPKD subjects who presented with hypertension
compared to ADPKD subjects who presented with normal
blood pressure [24].
One might speculate that the relationship between blood
pressure and earlier occurrence of renal disease reflects the role
of renal disease in the development of hypertension rather than
the reverse. However, the occurrence of hypertension in as
many as 75% of ADPKD subjects before renal dysfunction [25]
and its presence in childhood [2, 26] suggest that hypertension
contributes to worsening renal function and not vice versa. In
fact, in our patient population hypertension was first diagnosed
at a mean age of 34 years, well before the development of renal
insufficiency in most individuals. In addition, in most forms of
renal disease, hypertension is associated with a worse renal
outcome [27]. Hence ADPKD is likely not to be an exception.
Moreover, preliminary pathological data on early and late
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ADPKD suggest that hypertension-induced vascular abnormal-
ities play a central role in end-stage renal disease [28]. Ulti-
mately proof of a causal role of hypertension on renal dysfunc-
tion will depend upon the effect of control of blood pressure in
renal disease progression. It was important to demonstrate the
independent effects of hypertension and mean renal volume
since we have previously shown the interrelationship of these
aspects of ADPKD [29].
Since only a subset of ADPKD patients, albeit a large subset,
have extrarenal manifestations we have hypothesized that
patients so affected represent the more severe end of the
ADPKD spectrum and therefore may have more serious renal
disease as well, The lack of a significant effect of mitral valve
prolapse or intracranial aneurysm in the group as a whole and of
hepatic cysts in males does not support this hypothesis. Al-
though the occurrence of hepatic cysts in women was statisti-
cally associated with a worse renal outcome independent of
pregnancy, we queried if this relationship biologically reflected
the effect of pregnancy on both organs. Moreover, the relation-
ship may reflect other estrogen exposure which was not ana-
lyzed in this study. Milutinovic et al's study of 76 women
demonstrated no apparent adverse effect of pregnancy on renal
function [30]. However, the data were not longitudinal. Al-
though we did not demonstrate an effect of any pregnancy, with
three or more pregnancies the effect was highly significant.
Milutinovic et al [30] and our group [31] have shown the
frequent occurrence of new hypertension in ADPKD women
during pregnancy; moreover, we have demonstrated an in-
creased likelihood of sut tamed hypertension with increased
numbers of pregnancy. Therefore it would be reasonable to
speculate that pregnancy influence on renal function is due to its
effect on blood pressure. However, this can not explain the
total effect as both three or more pregnancies and hypertension
have statistically independent effects on renal function.
We were surprised by the effect of gross hematuria on renal
function and our data do not provide a pathogenetic explana-
tion. Nonetheless, it is intriguing to consider the role of gross
hematuria from cyst bleeding as a mechanism for increasing
intrarenal iron which in some models of renal failure has been
correlated with renal dysfunction [32].
Although urinary tract infections are common in ADPKD [3,
33], they have not been demonstrated to have an impact on the
progression of renal failure [13]. However, the studies were
small and relied on patient historical data. This latter issue is
critical since patients are likely to be diagnosed as having
urinary tract infection on the basis of flank pain, hematuria, and
pyuria which occur commonly in the absence of urinary tract
infection in ADPKD patients. This is a shortcoming of our
study as well and may explain why urinary tract infection was
associated with worse renal function only in men. We speculate
that the diagnosis may be made based more on actual data in
men than in women, while the diagnosis in women may often be
presumptively based on the frequency of cystitis. The signifi-
cant relationship in men nonetheless points out the potential for
a detrimental effect of urinary tract infections on renal function.
A relationship between renal size and renal function has been
suggested [20]. Dalgaard noted that the median time from
palpable kidneys to end-stage renal disease was less than five
years [18]. However, previous studies did not have the statis-
tical methodology to separate the effects of renal volume from
hypertension and aging which we have done to demonstrate a
very significant effect of renal volume. Nonetheless the way in
which cyst growth translates to progressive renal damage is not
known nor has it been demonstrated that cyst decompression
ameliorates the course [34, 35]. Recent studies of factors which
influence cyst growth [36, 37] may soon provide pharmacologic
ways to prevent cyst growth in obligate gene carriers which
would be an effective modality for eliminating the effect of
cystogenesis rather than the need to resort to decompression of
cysts in an already damaged organ.
Thus in ADPKD, end-stage renal disease is not inevitable in
a normal life span. Moreover, the progression to renal failure is
affected by multiple factors including both unalterable factors
such as gene type and gender and alterable factors such as
hypertension. Knowledge of the unalterable factors permits the
clinician to provide more effective counseling and prognostic
information to the patient. Knowledge of the alterable factors
may eventually provide an opportunity to ameliorate the pro-
gression of renal disease through clinical intervention. For the
investigator, identification of these factors provides an oppor-
tunity to focus investigational efforts on these aspects of
ADPKD with the goal of providing the clinician with tools to
ultimately prevent end-stage renal disease in ADPKD.
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